.png){kind=icon}
Y
Yuhuan Zheng
H-index:31
Citation Count:3,476
Views:0
Biography
No content for now.
Education
No content for now.
Work Experience
No content for now.
Honors & Awards
No content for now.
Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia
NPM1突变急性髓系白血病中继发型突变的不良预后意义
Cancer Medicine
IF3.1
The role of KPNA3 in multiple myeloma: implications for targeting nuclear import
KPNA3在多发性骨髓瘤中的作用：靶向核输入的意义
Apoptosis
IF8.1
Discovery of 2-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d] pyrimidine derivatives as novel HsClpP activators for multiple myeloma therapy
2-(甲基氨基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶衍生物作为新型HsClpP激活剂在多发性骨髓瘤治疗中的发现
Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma
新发肾功能不全在多发性骨髓瘤中的发生率、临床特征及预后价值
CANCER MEDICINE
IF3.1
LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma
LncRNA HCG11调控多发性骨髓瘤中selinexor的敏感性
The mitochondrial protease ClpP is a promising target for multiple myeloma treatment
线粒体蛋白酶ClpP是多发性骨髓瘤治疗的有希望的靶标
COMMD3 Regulates Copper Metabolism via the ATOX1-ATP7A-LOX Axis to Promote Multiple Myeloma Progression
COMMD3通过ATOX1-ATP7A-LOX轴调节铜代谢促进多发性骨髓瘤进展
BIOMEDICINES
IF3.9
Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study
奥雷巴替尼（Orelabrutinib）—一种布鲁顿酪氨酸激酶抑制剂为基础的治疗方案在边缘区淋巴瘤治疗中的应用：一项回顾性研究
BLOOD
IF23.1
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
基于Daratumumab的免疫疗法与来那度胺，硼替佐米和地塞米松在移植不合格的新诊断多发性骨髓瘤中的比较: 系统性回顾
